Acadia Pharmaceuticals Inc [ACAD] stock prices are down -0.35% to $19.67 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ACAD shares have gain 6.38% over the last week, with a monthly amount glided 11.95%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Acadia Pharmaceuticals Inc [NASDAQ: ACAD] stock has seen the most recent analyst activity on February 11, 2025, when Deutsche Bank initiated its Hold rating and assigned the stock a price target of $22. Previously, Guggenheim downgraded its rating to Neutral on January 03, 2025, and dropped its price target to $20. Morgan Stanley downgraded its rating to a Equal-Weight and decreased its price target to $20 on August 07, 2024. BMO Capital Markets initiated its recommendation with a Outperform and recommended $31 as its price target on June 27, 2024. Needham reiterated a Buy rating for this stock on March 12, 2024, and downed its price target to $32. In a note dated March 12, 2024, Mizuho downgraded an Neutral rating on this stock and revised its target price from $39 to $25.
The stock price of Acadia Pharmaceuticals Inc [ACAD] has been fluctuating between $14.15 and $26.56 over the past year. Currently, Wall Street analysts expect the stock to reach $20 within the next 12 months. Acadia Pharmaceuticals Inc [NASDAQ: ACAD] shares were valued at $19.67 at the most recent close of the market. An investor can expect a potential return of 1.68% based on the average ACAD price forecast.
Analyzing the ACAD fundamentals
The Acadia Pharmaceuticals Inc [NASDAQ:ACAD] reported sales of 929.24M for trailing twelve months, representing a surge of 18.28%. Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at 0.12%, Pretax Profit Margin comes in at 0.15%, and Net Profit Margin reading is 0.14%. To continue investigating profitability, this company’s Return on Assets is posted at 0.13, Equity is 0.26 and Total Capital is 0.18. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.09.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 19.47 points at the first support level, and at 19.26 for the second support level. However, for the 1st resistance point, the stock is sitting at 19.97, and for the 2nd resistance point, it is at 20.26.
Ratios To Look Out For
It’s worth pointing out that Acadia Pharmaceuticals Inc [NASDAQ:ACAD]’s Current Ratio is 2.29. Also, the Quick Ratio is 2.11, while the Cash Ratio stands at 0.45. Considering the valuation of this stock, the price to sales ratio is 3.52, the price to book ratio is 5.67 and price to earnings (TTM) ratio is 25.46.
Transactions by insiders
Recent insider trading involved Teehan Brendan, EVP, COO, HEAD OF COMMERCIAL, that happened on Nov 19 ’24 when 10329.0 shares were sold. PRINCIPAL ACCOUNTING OFFICER, Kihara James completed a deal on Nov 19 ’24 to sell 4073.0 shares. Meanwhile, EVP, CHIEF FINANCIAL OFFICER Schneyer Mark C. sold 10259.0 shares on Nov 19 ’24.
